View this email in your browser

November 2016

Upcoming events

December 2, 2016 

PhD thesis defense in Biological sciences: "Trypanosoma brucei"

UNamur, M01 auditorium


Arnaud Machelart will present his PhD thesis entitled "Impact de l'asthme allergique et de l'infection par Trypanosoma brucei sur le contrôle de l’infection par Brucella melitensis chez la souris" (promoter: Prof. Jean-Jacques Letesson)

December 5, 2016 

Lecture by Dr. Yann Guérardel (CNRS – Université de Lille), given in the frame of the master course of "Glycobiology"

UNamur, CH12 auditorium


"A story of the rise and fall of the mycobacterial cell wall"

December 5 & 20, 2016 

Seminars of the Research Pole in Infectiology

UNamur, B07 auditorium


December 6, 2016 

MIDI PUNCH: "Les étudiants-chercheurs, une autre façon d’apprendre"

UNamur, Salle académique de la Faculté d’informatique


This meeting will address the educational initiatives allowing students to gain a real experience in scientific research. Prof. Stéphane Lucas (Department of Physics, UNamur) and Prof. Jean-Michel Vandeweerd (Department of Veterinary Medicine, UNamur) will present how NARILIS encourages since 2010 bachelor students to perform mini-research projects and what are the benefits and challenges of these initiatives. 

December 6 & 13, 2016 

Chaire Bauchau - "Bactéries intestinales et métabolisme"

UNamur, M01 auditorium


December 13, 2016 

PhD thesis defense in Chemical sciences: "Non-nucleotide inhibitors of DNA"

UNamur, CH01 auditorium


Grégoire Rondelet will present his PhD thesis entitled "Structural study of non-nucleotide inhibitors of DNA (cytosine-5) methyltransferases" (promoter: Prof. Johan Wouters)

December 19, 2016 

Seminar given by Prof. Johanna Brandner (University Medical Center Hamburg-Eppendorf) - "Skin barrier function"

UNamur, L12 auditorium


"Tight junctions in the skin: No barrier is an island"

March 24-25, 2017 

Kick-off meeting of the Cancer Research Pole of NARILIS


More info coming soon!

March 30, 2017 

7th annual symposium of the Namur Thrombosis and Hemostasis Center

Château de la Poste, Maillen



The Rector of UNamur, Prof. Yves Poullet, scientific coordinator of an inter-university program of seminars on E-Health

The objective of these seminars is to review the promises and challenges of e-health technological developments.

More info

NARILIS Research Day

More than 80 scientists and clinicians gathered at the UNamur on the 17th of November 2016

Prof. Martine Raes, Vice-rector for Research of UNamur, and Prof. Jean-Christophe Renauld, Pro-rector for Research of UCL, were side-by-side to support NARILIS institute and to encourage multidisciplinary and collaborative research!
Furthermore, NARILIS key research areas were brilliantly showcased by pairs of Principal Investigators and young researchers.
See the presentations of the NARILIS Research Day:
Prof. M. Raes (UNamur)

Dr. F. Chainiaux (URBC, UNamur)
Dr. F. Potier (Geriatrics, CHU UCL Namur)

Prof. JM. Dogné (Pharmacy, UNamur)
Dr. JB. Nicolas (Internal Medicine, CHU UCL Namur)

Dr. JF. Daisne (Radiotherapy, CHU UCL Namur)
G. Sana (URPhyM, UNamur)

Prof. E. Marchand (Pulmonology, CHU UCL Namur)
Dr. S. Seldrum (Cardiology, CHU UCL Namur)

Prof. N. Caron (URPhyM, UNamur)
I. Jadot (URPhyM, UNamur)

Prof. X. De Bolle (URBM, UNamur)
P. Sacré (Microbiology lab, CHU UCL Namur)
Prof. Y. Vandermeeren (Neurology, CHU UCL Namur)
J. Bouchat (URPhyM, UNamur)

Prof. T. Arnould (URBC, UNamur)
Dr. Marielle Boonen (URPhyM, UNamur)

Prof. Y. Poumay (URPhyM, UNamur)
Dr. O. Vanhooteghem (Dermatology, CHU UCL Namur)

Prof. JF. Nisolle (Diagnostic imaging, CHU UCL Namur)
Dr. Fanny Hontoir (URVI, UNamur)

Prof. A. Castiaux (Business administration, UNamur)

Prof. PY. Schobbens (Computer Sciences, UNamur)

Dr. I. Dagneaux (Bioethics group, UNamur)

New NARILIS research publications

Increased risk of vascular occlusive events with new generation BCR-ABL tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia - Updated meta-analysis
In a previous meta-analysis, the NTHC highlighted that new generation tyrosine kinase inhibitors (TKIs), such as ponatinib, nilotinib and dasatinib, increase the risk of vascular occlusive events, compared to imatinib, the first TKI approved for the treatment of patients with chronic myeloid leukemia (Douxfils et al., 2016). More recently, a new meta-analysis of randomized controlled trials was performed to separately assess the risks of arterial and venous occlusive events. This new study indicates that vascular occlusive events associated with new generation BCR-ABL TKIs are mainly driven by arterial occlusive events.       
Impact of direct oral anticoagulants (DOACs) on activated clotting time
Atrial fibrillation (AF) is the most common type of arrhythmia. Catheter ablation is an invasive procedure used to treat AF, but which is associated with a significant risk of thrombotic events. Concomitant administration of unfractionated heparin and monitoring of the intraprocedural anticoagulation intensity using activated clotting time (ACT) is highly recommanded for lowering the complications.
Catheter ablation can be performed safely without interruption of DOACs therapy. However, little is known about the interference of these drugs with the ACT. Therefore, the NTHC performed an in vitro study by spiking blood samples collected from one healthy donor with 4 licensed DOACs, followed by ACT measurement. This preliminary work showed that dabigatran interferes more than anti-Xa agents (rivaroxaban, apixaban and edoxaban) on the ACT.
In vitro modeling of atopic dermatitis using reconstructed human epidermis
Atopic dermatitis is a chronic inflammatory skin disease, in which IL-4, IL-13 and IL-25, Th2 pro-inflammatory cytokines, are known to be key drivers of the underlying inflammatory process. The Cell and Tissue Laboratory of Prof. Yves Poumay and Prof. Catherine Lambert (URPhyM, UNamur) previously set up an in vitro model of atopic dermatitis (AD). They showed that plasma membrane cholesterol depletion using methyl-beta-cyclodextrin (MβCD) in reconstructed human epidermis (RHE), followed by exposure to a mixture of IL-4, IL-13 and IL-25, mimics the hallmarks of AD lesions. More recently, they completed this previous work by studying the role played by each individual IL. IL-4 incubation after MβCD treatment induced the strongest morphological alterations and weakening of barrier function in this RHE model.  
Involvement of S100A8/A9 in primary Sjögren's syndrome (pSS)
Sjögren's syndrome is a chronic inflammatory autoimmune disorder, characterized by lymphocytic infiltration of exocrine glands, in particular lacrimal and salivary glands. S100A8 and S100A9 are two calcium-binding proteins, mainly expressed as a heterodimer by phagocytes. S100A8/A9 heterodimer is known to play central roles in inflammatory processes. In collaboration with the Laboratory of Bone and Metabolic Biochemistry of the ULB and the Department of Rheumatology of the Erasme Hospital, Prof. Charles Nicaise (URPhyM, UNamur) studied the role of S100A8/A9 in the pathogenesis of pSS. Their study shows that the expression of S100A8/A9 is upregulated in pSS patients and triggers the secretion of pro-inflammatory cytokines by PBMCs in vitro.
For further research news, please visit NARILIS website

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NARILIS · Rue de Bruxelles 61 · Namur 5000 · Belgium

Email Marketing Powered by Mailchimp